<DOC>
	<DOCNO>NCT01809600</DOCNO>
	<brief_summary>This retrospective study aim evaluate safety efficacy rituximab-containing immunochemotherapy adult patient Burkitt 's lymphoma ( BL ) high-grade B-cell lymphoma , unclassifiable , feature intermediate diffuse large B-cell lymphoma BL .</brief_summary>
	<brief_title>Retrospective Analysis Rituximab-containing Immunochemotherapy Burkitt 's Burkitt-like Lymphoma Adults</brief_title>
	<detailed_description>Inclusion criterion 1. pathologically confirm BL BL-U World Health Organization 2008 criterion 2. age &gt; 20 yr 3. receive rituximab+chemotherapy first-line treatment 4. measurable evaluable lesion 5. complete set clinical laboratory data analysis</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. pathologically confirm Burkitt 's lymphoma ( BL ) High grade Bcell lymphoma , unclassifiable , feature intermediate diffuse large Bcell lymphoma BL ( BLU ) WHO 2008 criterion 2. age &gt; 20 yr 3. receive rituximab+chemotherapy firstline treatment 4. measurable evaluable lesion 1. patient BL BLU previously treat rituximab</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>